Johnson & Johnson is partnering with Pacira BioSciences for osteoarthritis of the knee, according to a July 22 news release.
The agreement adds Zilretta, an injectable osteoarthritis treatment, to Johnson & Johnson’s portfolio. The companies will also participate in shared professional education and initiatives to increase awareness of nonoperative care.
Zilretta is the first FDA-approved extended-release intra-articular therapy for patients with osteoarthritis-related knee pain. It uses a proprietary microsphere technology combining triamcinolone acetonide with a poly lactic-co-glycolic acid matrix.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
